NASDAQ · Drug Manufacturers - Specialty & Generic

Evolus, Inc. (EOLS) Stock

$7.01 -5.40% NASDAQ: EOLS Healthcare

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients.

Valuation

Metric	Value
Price	$7.01
Market Cap	$463.01M
P/E Ratio	-13.94
P/B Ratio	-15.40
P/S Ratio	1.51
EPS (TTM)	$-0.80
52-Week High	$9.31
52-Week Low	$3.86
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	123.11%
ROA	-13.84%
ROCE	-15.54%
Gross Margin	-12.79%
Operating Margin	-12.79%
Net Margin	-10.85%
Debt/Equity	-5.33
Current Ratio	1.91

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$100.0M	$149.0M	$202.0M	$266.0M	$297.0M
Operating Profit	$-44.0M	$-65.0M	$-49.0M	$-34.0M	$-38.0M
Net Profit	$-47.0M	$-74.0M	$-62.0M	$-50.0M	$-52.0M
EPS	$-0.94	$-1.33	$-1.08	$-0.81	$-0.80
Op Margin	-44.5%	-44.0%	-24.4%	-12.9%	-12.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$257.0M	$178.0M	$189.0M	$233.0M	$226.0M
Total Liabilities	$176.0M	$159.0M	$210.0M	$227.0M	$249.0M
Cash	$146.0M	$54.0M	$63.0M	$87.0M	$54.0M
Borrowings	$75.0M	$74.0M	$127.0M	$130.0M	$155.0M

Latest News

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 10, 2026 Evolus Partners With IBSA to Develop, Commercialize Profhilo in US MT Newswires · Jul 8, 2026 Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality Business Wire · Jul 8, 2026 3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80% Simply Wall St. · May 15, 2026 Evolus Plans to Launch Estyme Collection in Europe MT Newswires · May 11, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-33.0M	$-85.0M	$-34.0M	$-18.0M	$-42.0M
Investing Cash Flow	$3.0M	$-6.0M	$-3.0M	$-6.0M	$-17.0M
Financing Cash Flow	$-6.0M	$-4.0M	$-5.0M	$-4.0M	$16.0M
Net Cash Flow	$44.0M	$-92.0M	$9.0M	$24.0M	$-33.0M
Free Cash Flow	$-34.0M	$-88.0M	$-36.0M	$-19.0M	$-51.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.20
EV / EBITDA	-84.37
FCF Yield	-4.13%
Quick Ratio	1.28
Interest Coverage	-1.43
Return 1Y	-37.47%
Return 3Y	-16.92%
Return 5Y	-46.31%

Ownership

Insiders Held14.68%

Institutions Held70.35%

Institutions Float Held82.46%

Institutional Holder	Shares	Report Date
Nantahala Capital Management, LLC	6,376,857	2026-03-31
Blackrock Inc.	4,290,383	2026-03-31
Braidwell LP	3,105,209	2026-03-31
Frazier Life Sciences Management, L.P.	2,630,665	2026-03-31
Vanguard Capital Management LLC	2,470,408	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AEONAEON Biopharma, Inc.	$0.24	+2.65%	-0.06	$11.97M	0.00%

About Evolus, Inc.

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Evolus, Inc. is led by CEO David Moatazedi, employs 372 people, headquartered in US, publicly traded since 2018.

Evolus, Inc. (EOLS) stock trades at $7.01 with a market capitalization of $463.01M. The stock is valued at a negative price-to-earnings (P/E) ratio of -13.94, reflecting a net loss over the last twelve months, a negative price-to-book of -15.40, reflecting negative shareholders' equity, price-to-sales of 1.51. Over the past 52 weeks the stock has ranged between $3.86 and $9.31, and currently trades 24.7% below its 52-week high.

On profitability, Evolus, Inc. generates a return on equity (ROE) of 123.11% (not meaningful, as shareholders' equity is negative), return on capital employed of -15.54%, an operating margin of -12.79%, a net profit margin of -10.85%.

Official website: www.evolus.com

Evolus, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Evolus, Inc. reported revenue of $0 rising to $297.0M. Compounded, revenue has grown 39.1% a year over five years, 25.9% over three, 11.7% over the last twelve months. Net profit fell to $-52.0M.

The most recent net margin is -10.85%. On a trailing twelve-month basis to Jun '26, revenue is $316.0M and net profit $-35.0M.

Borrowings rose from $60.0M to $155.0M, cash on hand is $45.0M, cash from operations was $-42.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -156.1% over five years, and was 226.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Evolus, Inc. (EOLS) — frequently asked questions

What is Evolus, Inc. (EOLS) stock price today?

Evolus, Inc. (EOLS) is currently trading at $7.01, down 5.4% today.

What is EOLS P/E ratio?

Evolus, Inc.'s P/E ratio is -13.94. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is EOLS return on equity (ROE)?

Evolus, Inc.'s return on equity (ROE) is 123.11%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Evolus, Inc.'s market cap?

Evolus, Inc. has a market capitalization of $463.01M.

Does EOLS pay a dividend?

Evolus, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does EOLS carry?

Evolus, Inc. has a debt-to-equity ratio of -5.33. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is EOLS's profit margin?

Evolus, Inc. reports a net profit margin of -10.85% — the share of revenue left after every cost, including tax and interest.

What sector is EOLS in?

Evolus, Inc. is classified under Healthcare, in the Drug Manufacturers - Specialty & Generic industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is EOLS listed on?

Evolus, Inc. trades on NASDAQ under the ticker EOLS.

What is EOLS's 52-week range?

Over the last year Evolus, Inc. has traded between $3.86 and $9.31.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Screens EOLS currently matches

On the figures above, Evolus, Inc. passes the filters for 6 of our ready-made screens, among them Day Losers Stocks, Small Cap Stocks, Stocks Under $10. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Day Losers Stocks Small Cap Stocks Stocks Under $10 Stocks Under $100 Stocks Under $50 High ROE Stocks Under $100

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.